Register for our free email digests:
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Perrigo Remains Committed To Splitting Off Prescription Despite Delay
Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.
China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal
China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.
Cipla Sees Muted First Quarter Amid Distributor 'Churn' In India
A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.
Akorn Sees A $10m Increase In FDA Compliance Expenditure
Akorn’s second-quarter results show a drop in sales despite the launch of three new products. The company expects a $10m increase in FDA compliance and data-integrity assessment expenditures because of a warning letter issued over its Somerset manufacturing facility.
Mallinckrodt Delays Generics Spinoff
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.
Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight
Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.